Freenome Reports Q3 2026 Profit Driven by FDA Approval and Abbott Partnership
Freenome (FRNM) reported a significant financial turnaround in the third quarter of 2026, posting a GAAP net income of $60.1 million compared to a loss in the prior year. This profitability was primarily driven by $182.5 million in license and collaboration revenue following the FDA approval of its SimpleScreen CRC colorectal cancer screening test. The company's strategic partnership with Abbott continues to provide substantial liquidity, with Freenome having received $242.2 million of a potential $885 million in milestone payments. The commercial launch of SimpleScreen CRC has seen rapid clinical interest, with 2,000 sites requesting collection kits within the first month and an established Medicare reimbursement rate of $920 per test. Looking ahead, Freenome maintains a strong cash position of $430 million. While R&D expenses increased due to stock-based compensation, management updated full-year 2026 revenue guidance to between $192 million and $194 million, reflecting the company's transition into a public entity with active commercial operations.

Topics: clinical study results FDA approval net income partnership milestones revenue